Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that it has enrolled the first patient in the Phase IV clinical trial of Azilect. The study will evaluate the cognitive function in adults with mild cognitive impairment in Parkinson's disease.
The study will evaluate the effect of Azilect on cognitive function in adults with mild cognitive impairment in Parkinson's, as assessed by the Scales for Outcomes of Parkinson's Disease-Cognition after 24 weeks of treatment. The study includes 170 patients at 30 sites in the US.
“Cognitive impairment in Parkinson's disease is a major cause of disability and increased care partner burden,” said Dr. Robert A. Hauser, director of the Parkinson's Disease & Movement Disorders Center at the University of South Florida, the co-primary investigator of the study. “As currently there are no available treatments for cognitive impairment in Parkinson's disease, any therapy that may demonstrate benefit would be welcomed for this significant unmet need."
Teva chief scientific officer and president Global R&D Dr. Michael Hayden said, “Mild cognitive impairment in Parkinson's disease is common in non-demented Parkinson's patients and is associated with increasing age, disease duration and disease severity."
Published by Globes [online], Israel business news - www.globes-online.com - on February 5, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013